| |

Breath Test for Mesothelioma Might Identify Subtypes

Breath Test for Mesothelioma

Researchers in the UK say a breath test for mesothelioma might be able to distinguish between mesothelioma subtypes.

There are three major subtypes of mesothelioma. It is important to know which kind of person has. A patient’s subtype can impact their prognosis and even their mesothelioma treatment choice. 

Right now, the only way to tell the mesothelioma subtypes apart is to look at the cells under the microscope. But scientists at Sheffield Hallam University have identified volatile organic compounds (VOCs) in the rarest and the most common mesothelioma subtypes. 

These VOCs could be used to develop a mesothelioma breath test that could tell the subtypes apart. 

The Advantages of Breath Testing

Breath testing is a way of measuring VOCs in a person’s exhaled breath. By analyzing these compounds, doctors may be able to tell if a patient has cancer or another illness. Scientists are still working on a breath test for mesothelioma.

There are several advantages of breath analysis over other kinds of tests. For one thing, a breath test is non-invasive. Other kinds of mesothelioma tests require a biopsy or at least the extraction of blood or lung fluid. 

No scalpels or needles are needed for a breath test. This kind of test is also less expensive than other tests and the results are faster. With a biopsy, a pathologist has to use a microscope to look at mesothelioma cells.  But breath testing does not require a pathologist. If it leads to earlier diagnosis and treatment, such a test could even save lives. 

Three Different Cell Types Tested

There are limits to the mesothelioma VOC tests that have been tested so far. One big one is that a breath test for mesothelioma cannot tell the different subtypes apart. This can only be done by looking at the cells. 

But the new research at Sheffield Hallam University could help change that. The scientists focused on three types of cells – biphasic, epithelioid, and non-malignant mesothelial. 

Biphasic is the rarest mesothelioma subtype. Epithelioid is the most common. Mesothelial cells come from the membrane where mesothelioma tumors start. The researchers used them as a control group.

VOCs Key to a Breath Test for Mesothelioma

The new study used a headspace analyzer to measure the VOCs released by each type of cell. Headspace gas chromatography is a way of separating VOCs from a liquid or solid for analysis.  

“2-ethyl-1-hexanol was significantly increased in both MSTO-211H [biphasic] and NCI-H28 [epithelioid] cells compared to MET-5A [healthy cell] controls,” writes study author Liam David Little. “In addition, ethyl propionate and cyclohexanol were significantly increased in MSTO-211H cells and dodecane was significantly increased in NCI-H28 cells.”

A breath test for mesothelioma that measures these VOCs might be able to distinguish one subtype from another. This is the first study to consider the impact of mesothelioma subtype on VOC profile. 

The report concludes, “Current results further highlight the potential for a diagnostic mesothelioma breath test as well as providing proof of concept for the differentiation between biphasic and epithelioid mesothelioma based on VOC profiles.”

No one knows yet if breath testing can really detect mesothelioma. None of the previous studies have been big enough for the technique to be universally recommended. 

Source: 

Little, LD, et al, “Headspace analysis of mesothelioma cell lines differentiates biphasic and epithelioid sub-types”, July 30, 2020, Journal of Breath Research, Epub ahead of print, https://iopscience.iop.org/article/10.1088/1752-7163/abaaff

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • |

    New Prognostic Factor in Peritoneal Mesothelioma

    Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…

  • | |

    FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

    In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

  • | |

    Mesothelioma Surgeons Report New Biopsy Technique

    A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…